Fairchild Semiconductor Intl, Inc. FCS
19.86 0.00 (+0.00%)
At closeJun 28, 2019, 6:07 PM EDT
19.84 Day range 19.88
12.95 52-week range 21.71
- Volume
- 937.61K
- Avg volume
- 1.60M
- Open
- 19.88
- Previous close
- 19.86
- Day's range
- 19.84 – 19.88
- 52-week range
- 12.95 – 21.71
- Earnings date
- Oct 20, 2016
No chart data for this range yet.
Next earnings
Oct 20, 2016
Expected Oct 20, 2016. Consensus EPS estimate 0.19.
Financials — quick view
FCS Revenue — quarterly 350.00M
FCS Net income — quarterly 6.90M
FCS EPS — quarterly 0.06
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 20, 2016 | Sep 1, 2016 | 0.19 | — | — | — |
| Aug 8, 2016 | Jun 1, 2016 | 0.16 | — | — | — |
| Apr 21, 2016 | Mar 1, 2016 | 0.13 | — | — | — |
| Jan 28, 2016 | Dec 1, 2015 | 0.14 | — | — | — |
| Oct 15, 2015 | Sep 1, 2015 | 0.20 | — | — | — |
| Jul 16, 2015 | Jun 1, 2015 | 0.19 | — | — | — |
News
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides 
NICE issues final draft guidance recommending ▼ Tryngolza® (olezarsen) as an option to treat genetically confirmed familial chylomicronaemia syndrome (FCS) in adults in England and Wales 
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia 
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia 
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides 
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia 
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG) 
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) 
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress 
Esquire Bank Earns Multiple Honors at 2026 FCS Portfolio Awards
Your note
Sign in to keep a note on FCS — it syncs with the Stock Master app.